Evidence map›Paper›PMID 20407744›Full record

ArticleDiabetologia2010

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

S L Bowker, Y Yasui, P Veugelers, J A Johnson

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 8 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 8 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
    Pooled it
  9. Trial
  10. Article
  11. Review
  12. Metformin: A Dual-Role Player in Cancer Treatment and Prevention.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. The quest to slow ageing through drug discovery.Nature reviews. Drug discovery · 2020
    Review
  19. Energy metabolism in cancer stem cells.World journal of stem cells · 2020
    Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S L BowkerDepartment of Public Health Sciences, School of Public Health, University of Alberta, 2-040 Health Research Innovation Facility, Edmonton, AB, Canada T6G 2E1.
Y Yasui
P Veugelers
J A Johnson
University of Alberta · CA

Funding

Canadian Institutes of Health Research MOP-82737Canadian Institutes of Health Research OTG-88588
6 · The paper itself

Abstract

aims/hypothesisWe explored the relationship between glucose-lowering agents and cancer mortality rates in type 2 diabetes patients, hypothesising a decreased risk of cancer mortality with metformin use and a dose-risk gradient for insulin therapy.

methodsThis was a population-based cohort study using administrative data from Saskatchewan Health, Canada. We identified new users of metformin or sulfonylureas from 1 January 1991 to 31 December 1996, with follow-up until death, departure from the province or 31 December 1999. Cox regression analyses were used to estimate the HR of death from cancer, accounting for time-varying exposure to metformin, sulfonylurea, and exogenous insulin therapy.

resultsWe identified 10,309 new users of metformin or sulfonylurea. The average follow-up was 5.4 (1.9) years, during which 407 (4.0%) cancer deaths occurred. Adjusting for age, sex and chronic disease score, the adjusted HR for metformin use was 0.80 (95% CI 0.65-0.98) compared with sulfonylurea monotherapy users. Adjusted HRs for subsequent insulin use were 2.22 (0.99-5.00), 3.33 (2.26-4.89) and 6.40 (4.69-8.73) for <3, 3 to 11 and > or = 12 insulin dispensations/year, respectively, compared with patients not on insulin. We observed a similar risk gradient among the sub-cohort of new insulin users. CONCLUSIONS/

interpretationOur results support previous reports of a decreased risk of cancer outcomes associated with metformin use relative to sulfonylurea monotherapy. We also provide new evidence of a gradient of cumulative insulin dispensations and cancer mortality rates.

Indexed as

Databases, FactualDiabetes Mellitus, Type 2Drug Therapy, CombinationHumansHypoglycemic AgentsInsulinMetforminNeoplasmsSaskatchewanSulfonylurea CompoundsTime FactorsTreatment OutcomeHypoglycemic AgentsInsulinMetforminSulfonylurea Compounds

Identifiers

PMID20407744
OpenAlexW2017281521

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.